An Integrated clinical pathway for diagnosis, treatment and care of rare diseases: model, operating procedures, and results of the project TRANSLATE-NAMSE funded by the German Federal Joint Committee

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Daniela Choukair - , Heidelberg University  (Author)
  • Fabian Hauck - , Ludwig Maximilian University of Munich (Author)
  • Markus Bettendorf - , Heidelberg University  (Author)
  • Heiko Krude - , Charité – Universitätsmedizin Berlin (Author)
  • Christoph Klein - , Ludwig Maximilian University of Munich (Author)
  • Tobias Bäumer - , University of Lübeck (Author)
  • Reinhard Berner - , Department of Paediatrics, TUD Dresden University of Technology (Author)
  • Min Ae Lee-Kirsch - , Department of Paediatrics, TUD Dresden University of Technology (Author)
  • Corinna Grasemann - , Ruhr University Bochum (Author)
  • Peter Burgard - , Heidelberg University  (Author)
  • Georg F. Hoffmann - , Heidelberg University  (Author)

Abstract

Background: Diagnosis, treatment, and care of patients with rare diseases require multidisciplinary cooperation between medical and paramedical specialities and with patients and families. Innovative genetic diagnostics, whole exome and whole genome sequencing (WES, WGS) has enlarged the diagnostic toolkit but also increased the complexity of the endeavour. Structured multidisciplinary clinical pathways (CPW) can guide diagnosis, treatment, and care of patients with rare diseases, link scientific evidence to clinical practice and optimise clinical outcomes whilst maximising clinical efficiency. Results: In contrast to the common approach of appending disease-specific CPWs to disease-specific guidelines, we suggest a generic CPW manoeuvring the patient along the way of finding the correct diagnosis by applying the best diagnostic strategy into an appropriate system of treatment and care. Available guidelines can be integrated into the generic CPW in the course of its application. The approach also applies to situations where a diagnosis remains unsolved. The backbone of the generic CPW is a set of multidisciplinary structured case conferences projecting and evaluating diagnostic and/or therapeutic steps, enforcing to integrate best scientific evidence with clinical experience. The generic CPW is stated as a flowchart and a checklist which can be used to record and document parsimoniously the structure, process and results of a patient’s pathway, but also as a data model for research. It was applied in a multicentre setting with 587 cases each with a presumptive diagnosis of a rare disease. In 369 cases (62.8%) a diagnosis could be confirmed, and multidisciplinary treatment and/or care was initiated. The median process time from first contact until confirmation of diagnosis by WES was 109 days and much shorter than diagnostic delays reported in the literature. Application of the CPW is illustrated by two case reports. Conclusions: Our model is a tool to change the diagnostic odyssey into an organised and trackable route. It can also be used to inform patients and families about the stages of their individual route, to update health care providers only partially involved or attending specialised treatment and care, like the patient’s or family’s primary physician, and finally to train novices in the field.

Details

Original languageEnglish
Article number474
JournalOrphanet journal of rare diseases
Volume16
Issue number1
Publication statusPublished - Dec 2021
Peer-reviewedYes

External IDs

PubMed 34772435

Keywords

Keywords

  • Case management, Clinical pathway, Diagnostic odyssey, Evidence-based medicine, Rare diseases